LONDON (Thomson Financial) - Futura Medical PLC said it remains confident
of securing a licensing deal for its over-the-counter erectile dysfunction treatment, MED2002.
The pharmaceutical group, which develops innovative products for consumer healthcare, said the European Union approval of CSD500 remains on track for Q4, and the company is looking forward to making the transition to a revenue generating business with a recurring royalty stream.
In an AGM statement, chairman William Potter also said: 'We continue to make progress on our earlier-stage portfolio and in seeking new applications for our novel drug delivery technology, DermaSys'.
COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.